相关实验视频
Updated: Jun 16, 2025

08:50
Prostaglandin Extraction and Analysis in Caenorhabditis elegans
Published on: June 25, 2013
19.5K
通过测量前列腺素E主要尿代谢物 (PGE-MUM) 来确定耐火性性结肠炎的治疗策略
Ryosuke Miyamoto1, Hitoshi Honma1, Yu Masuda1
1Department of Pediatrics, Aichi Medical University, Nagakute, JPN.
Cureus
|August 16, 2024
概括
前列腺素E主要尿代谢物 (PGE-MUM) 水平在严重的性结肠炎病例中表明了T-辅助体17的特征. 测量PGE-MUM指导了成功使用mirikizumab,一种抗干白素-23疗法,导致缓解.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 生物标志物发现发现
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性肠病.
- 耐药病例带来了重大的治疗挑战.
- 细胞因子概况对于了解UC病原体至关重要.
相关概念视频
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
377
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
377
Peptic Ulcer Disease IV: Management
78
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
78
Drugs for Treatment of Ulcerative Colitis in IBD
131
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
131
Inflammatory Bowel Disease IV: Pharmacological Management
124
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
124
Inflammatory Bowel Disease V: Surgical Management
134
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
134
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
162
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
162

